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Abstract
Introduction: Estrogen receptor positive breast cancers often have high levels of Mdm2. We investigated if
estrogen signaling in such breast cancers occurred through an Mdm2 mediated pathway with subsequent
inactivation of p53.
Methods: We examined the effect of long-term 17b-estradiol (E2) treatment (five days) on the p53-Mdm2 pathway
in estrogen receptor alpha (ERa) positive breast cancer cell lines that contain wild-type p53 (MCF-7 and ZR75-1).
We assessed the influence of estrogen by examining cell proliferation changes, activation of transcription of p53
target genes, p53-chromatin interactions and cell cycle profile changes. To determine the effects of Mdm2 and p53
knockdown on the estrogen-mediated proliferation signals we generated MCF-7 cell lines with inducible shRNA for
mdm2 or p53 and monitored their influence on estrogen-mediated outcomes. To further address the p53-
independent effect of Mdm2 in ERa positive breast cancer we generated cell lines with inducible shRNA to mdm2
using the mutant p53 expressing cell line T-47D.
Results: Estrogen increased the Mdm2 protein level in MCF-7 cells without decreasing the p53 protein level. After
estrogen treatment of MCF-7 cells, down-regulation of basal transcription of p53 target genes puma and p21 was
observed. Estrogen treatment also down-regulated etoposide activated transcription of puma, but not p21. Mdm2
knockdown in MCF-7 cells increased p21 mRNA and protein, decreased cell growth in 3D matrigel and also
decreased estrogen-induced cell proliferation in 2D culture. In contrast, knockdown of p53 had no effect on
estrogen-induced cell proliferation. In T-47D cells with mutant p53, the knockdown of Mdm2 decreased estrogen-
mediated cell proliferation but did not increase p21 protein.
Conclusions: Estrogen-induced breast cancer cell proliferation required a p53-independent role of Mdm2. The
combined influence of genetic and environmental factors on the tumor promoting effects of estrogen implicated
Mdm2 as a strong contributor to the bypass of cell cycle checkpoints. The novel finding that p53 was not the key
target of Mdm2 in the estrogen activation of cell proliferation could have great benefit for future Mdm2-targeted
breast cancer therapies.
Introduction
While the p53 gene is the most commonly mutated gene
in human cancers [1], p53 mutations in breast cancers
occur in only 20% of cases [2-4]. Breast cancer cells with
wild-type p53 often have high levels of the oncogenic
protein Mdm2 suggesting that Mdm2 might block the
function of p53 [5-7]. In addition, elevated expression of
Mdm2 occurs in estrogen receptor a positive (ERa +)
breast cancer cells independently of p53 using evolutio-
narily conserved AP1 and ETS family transcription fac-
tors [8]. Two-thirds of breast cancers demonstrate
estrogen-dependent growth [9]. In response to estrogen,
ERa induces transcription of target genes to activate cell
proliferation and survival [10,11]. This could be, in part,
through coordinated activation of cell proliferation and
inhibition of cell death. Estrogen induces expression of
the anti-apoptotic gene bcl-2 thus inhibiting apoptosis
[12] and also stimulates Myc expression to aid in cell
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pathway because ERa can inhibit p53 transcriptional
activity by interacting with p53 on the chromatin [13,14].
While Mdm2 has been implicated in estrogen’sm e c h a n -
ism of action, the role that Mdm2 plays in this process
has not been clearly defined [6,15-17]. Mdm2 expression
is increased in the presence of estrogen [8,18] and Mdm2
enhances the function of ERa [19]. A cancer predisposi-
tion single nucleotide polymorphism at position 309 in
the mdm2 gene P2 promoter (T®G) increases binding
affinity for the SP1 transcription factor, leading to Mdm2
over-expression [20]. The Mdm2 SNP309 G allele has
also been associated with inhibition of the p53-Mdm2
pathway [20,21]. In cancer cells that are homozygous
G/G for the Mdm2 SNP309, the Mdm2 protein remains
associated with the chromatin as a p53-Mdm2 complex
resulting in compromised p53 trans-activation [21].
Moreover, the mdm2 SNP309 G allele associates with
accelerated tumor formation in a gender-specific and
hormone-dependent manner [6]. Therefore, the connec-
tion between estrogen and Mdm2 implicates inhibition
of p53 as a possible mechanism of action.
In normal cells mdm2 transcription is activated by p53
[22] and Mdm2 protein functions to target p53 for pro-
teolysis [23,24]. Mdm2 also inhibits p53 transactivation
by blocking p53 association with the transcription
machinery [25-28]. Additionally, Mdm2 mediates histone
ubiquitination leading to repression of p53 targets [29].
Mdm2 has also been shown to target p21 for proteasomal
turnover independently of ubiquitination [30]. Mdm2
may impart some of its tumorigenic properties by
increasing the degradation of multiple cellular proteins.
If Mdm2 is blocking the p53-pathway in estrogen
receptor positive breast cancer cells then the conven-
tional chemotherapeutics that rely on the p53 tumor
suppressor, a major cell death regulator [31], may not
activate cell death effectively. p53 acts by promoting
expression of numerous genes which control cell cycle
arrest, senescence, apoptosis, DNA repair, genomic sta-
bility and survival [32]. p53 also plays a pro-apoptotic
role by activating target genes that produce products
that dimerize with Bcl-2, one critical target of this type
is puma [33]. Endocrine therapy is used in ERa+b r e a s t
cancers and this reduces Bcl-2 levels, however, due to
acquired resistance other treatment options need to be
identified [34]. The involvement of the p53-Mdm2 path-
way in estrogen’s influences places this pathway at the
forefront of our investigation.
Using inducible gene silencing of mdm2 and p53 we
examined if the p53-Mdm2 pathway was required for
estrogen-mediated cell proliferation. We found that a
p53-independent role for Mdm2 participated in estro-
gen-induced proliferation of MCF-7 and T-47D breast
cancer cells. Inducible knockdown of Mdm2 in MCF-7
cells with wild-type p53 decreased cell proliferation and
increased p21. Moreover, inducible gene silencing of
mdm2 caused a reduction in the estrogen-induced target
Bcl-2. Inducible knockdown of Mdm2 in estrogen trea-
ted T-47D cells with oncogenic mutant p53 decreased
cell proliferation without increasing p21. Our data
suggest that estrogen activates cell proliferation using
Mdm2 to repress multiple cell cycle checkpoints as evi-
denced by comparison of MCF-7 and T-47D outcomes
following inducible shRNA mediated knockdown of
Mdm2.
Materials and methods
Cell culture
MCF-7 (p53 wild-type, mdm2 SNP309 T/G), T-47D
(oncogenic mutant p53 L194F, mdm2 SNP309 G/G) and
ZR75-1 (p53 wild-type, mdm2 SNP309 T/T) from
American Type Culture Collection (ATCC). MCF-7 and
ZR75-1 cells were grown in RPMI 1640 medium
(Mediatech) and T-47D cells were grown in DMEM
medium (Invitrogen, Carlsbad, CA, USA). Both media
were supplemented with 10% FBS (Gemini, West Sacra-
mento, CA, USA) and 2,500 units of penicillin-strepto-
mycin (Mediatech, Herndon, VA, USA) at 5% CO2 37°C
humidified incubator. We generated constructs with
inducible (TET-ON) shRNA for mdm2 and p53 or with-
out the shRNA oligonucleotide (a generous gift from
Scott Lowe). Constructs were introduced into the MCF-
7 cells (mdm2 or p53 shRNA) and T-47D cells (mdm2
shRNA) by retrovirus mediated gene transfer method.
Briefly, Phoenix packaging cells were transfected by cal-
cium phosphate method with either an rtTA plasmid or
with a vector containing mdm2, p53 or no shRNA oligo.
The generated viruses were harvested and MCF-7 cells
or T-47D cells were co-infected with the rtTA plasmid
and one of the vectors. After selection with puromycin
(vector with shRNA) and hygromycin (rtTA), clonal cell
lines were generated by limited dilution method. Clonal
cell lines were selected based on the level of Mdm2 or
p53 knockdown. Experiments shown were carried out
on clonal cell lines. MCF-7 mdm2 shRNA 151656 clone
C4; T-47D mdm2 shRNA 151657 clone 3B6; MCF-7
p53 shRNA 2120 clone D11. To induce shRNA expres-
sion, cells were treated with 2 μg/ml doxycycline (DOX)
for time periods indicated in the figures.
Treatments
Estrogen (17b-estradiol, E2), Etoposide and DMSO were
purchased from Sigma, Saint Louis, MO, USA. 24 hours
prior to treatments, growth medium was changed to
phenol-red-free RPMI 1640 (for MCF-7 cells) or DMEM
(for T-47D cells) containing 10% charcoal-stripped FBS
(Gemini) and antibiotics. Fresh medium was supplemen-
ted every 72 hours.
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RNA was isolated using QIAshredder columns and
RNeasy Mini Kit (Qiagen, Valencia, CA, USA). A total of
5 μg of RNA was used for cDNA synthesis using High
Capacity cDNA Archive Kit reagents (Applied Biosystems,
Foster City, CA, USA). 150 ng of cDNA was combined
with Taqman Universal Master Mix (Applied Biosystems,
Foster City, CA, USA) and Applied Biosystems Assays on
Demand primers/probes for puma (Hs00248075_m1),
mdm2 (Hs00242813_m1),p 2 1(Hs00355782_m1) or
ACTIN (4352935E). PCR reaction was carried out in 7500
Sequence Detection System (Applied Biosystems). P-values
were calculated by student t-test.
Whole cell protein extract
Cells were lysed in RIPA buffer (0.1% SDS, 1% NP-40,
0.5% Deoxycholate, 150 mM NaCl, 1 mM EDTA,
0.5 mM EGTA, 50 mM Tris-Cl pH8) with 1 mM PMSF,
8.5 μg/ml Aprotinin and 2 μg/ml Leupeptin following
standard protocol.
Western blot
A total of 50 μg of protein extract were separated by 10%
SDS-PAGE and electro-transferred to nitrocellulose mem-
brane. Immunoblotting was done with p53 antibodies
(a 1:1:1 mix of hybridoma supernatants, pAb421, pAb240
and pAb1801); Mdm2 in MCF-7 and ZR75-1 cells (SMP-
14 Santa Cruz sc-965, Santa Cruz Biotechnology, Santa
Cruz, CA, USA); Mdm2 in T-47D cells (a 1:1:1 mix of
hybridoma supernatants, 4B2, 2A9 and 4B11); Bcl-2 (100
Santa Cruz sc-509); PUMA (Cell Signaling 4976, Danvers,
MA, USA); p21 (Ab-1 Oncogene Research Science OP64,
Gibbstown, NJ, USA); Actin (Sigma A2066). To detect p21
protein in T-47D cells, 100 μg of protein extract was
transferred to a PVDF membrane.
Immunofluorescence
Cells, grown and treated on coverslips, were fixed with
4% Formaldehyde and permeabilized with 0.5% Triton-
X-100. Immunohistochemistry was done with p53
(FL-393 Santa Cruz sc-6243) and Mdm2 (SMP-14 Santa
Cruz sc-965) antibodies followed by incubation with
FITC-conjugated anti-mouse (Jackson ImmunoResearch
715-095-150, West Grove, PA, USA) and Alexa-
conjugated anti-rabbit (Invitrogen A11037). Coverslips
were mounted onto slides using Vectashield mounting
medium with DAPI (Fisher Scientific NC9524612, Pitts-
burgh, PA, USA). Images were collected by PerkinElmer
UltraVIEW ERS Spinning Disc Microscope, Waltham,
MA, USA.
Chromatin immunoprecipitation (ChIP)
Cells were incubated with 1% Formaldehyde for
30 minutes at 5% CO2 37°C humidified incubator,
followed by 0.125 M Glycine treatment for 5 minutes.
Cells were lysed in RIPA buffer with 1 mM PMSF,
8.5 μg/ml Aprotinin, 2 μg/ml Leupeptin and Phospha-
tase Inhibitor Cocktail 1 (Sigma)). Lysates were soni-
cated 10 times (one minute pulse and one minute rest)
in a Branson Digital Sonifier, Danbury, CT, USA and
spun down for 30 minutes 13,000 rpm at 4°C. 400 μg
of protein from cell lysates were subjected to overnight
incubation at 4°C with 2 μg of p53 (Ab-6 Calbiochem
O P 4 3 ,G i b b s t o w n ,N J ,U S A ) ;M d m 2( N - 2 0S a n t aC r u z
sc-813); or non-specific IgG (Santa Cruz, IgG mouse
sc-2025, IgG rabbit sc-2027). 50 μlo f2 5 %b e a d ss l u r r y
of protein A/G Plus Agarose beads (Santa Cruz
sc-2003), pre-blocked with 0.3 mg/ml sheared herring
sperm DNA (Invitrogen, 15634-017), were added to
immunoprecipitation samples for two hours at 4°C, fol-
lowed by washes: (1) 0.1% SDS, 1% Triton-X-100,
20 mM Tris pH8.1, 150 mM NaCl; (2) 0.1% SDS, 1%
Triton-X-100, 20 mM Tris pH8.1, 500 mM NaCl;
(3) 0.25 M LiCl, 1% NP-40, 1% Deoxycholate, 1 mM
E D T A ,1 0m MT r i sp H 8 ;a n d(4) twice with TE pH8.
Immunoprecipitated chromatin was de-crosslinked
overnight at 65°C with 1 mg/ml ProteinaseK, 1% SDS
and 0.1M NaHCO3. For total DNA input, 40 μgw e r e
similarly de-crosslinked. DNA fragments were purified
using Qiagen QiaQuick kit (Qiagen) and amplified by
real-time quantitative PCR in 7500 Sequence Detection
System (Applied Biosystems). Primers and probes
sequences are based on [35], and are provided below:
puma:
forward primer: GCGAGACTGTGGCCTTGTGT;
reverse primer: CGTTCCAGGGTCCACAAAGT;
probe: TGTGAGTACATCCTCTGGGCTCTGCCTG.
mdm2:
forward primer: GGTTGACTCAGCTTTTCCTCTTG;
reverse primer: GGAAAATGCATGGTTTAAA
TAGCC;
probe: GCTGGTCAAGTTCAGACACGTTCCGAA.
p21:
forward primer: GTGGCTCTGATTGGCTTTCTG;
reverse primer: CTGAAAACAGGCAGCCCAA;
probe:
TGGCATAGAAGAGGCTGGTGGCTATTTTG.
mdm2 siRNA transfection
Cells were seeded in media with no antibiotics. After
24 hours, 10 μl Lipofectamine2000 (Invitrogen) was incu-
bated for 5 minutes with 240 μl Optimem (Invitrogen).
0.2 nmol (100 nM) of non-specific or mdm2 siRNA
(Dharmacon) were resuspended in 250 μl Optimem and
combined with Lipofectamine2000. After 20 minutes,
500 μl siRNA-Lipofectamine2000 mix was added to cells
with 1.5 ml Optimem. Six hours later, complete growth
media was supplemented.
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Number of cells was determined by the Guava Viacount
assay according to manufacturer’s protocol (Millipore,
Lincoln Park, NJ, USA). Graphs show means and stan-
dard errors of three independent experiments. P-values
were calculated by student t-test.
Fluorescence activated cell sorting (FACS)
FACS was performed on a FACScan (BD Biosciences,
San Jose, CA, USA). After treatments, cells were har-
vested, washed, resuspended in PBS containing 2%
bovine serum albumin, 0.1% sodium azide, fixed in 30%
ethanol, and stored overnight at 4°C. Before sorting,
propidium iodide staining and RNase treatment were
performed for 30 minutes at 37°C.
Cell culture in matrigel
MCF-7 cells were seeded at a density of 5 × 10
3 cells per
chamber in an eight chamber slide on top of 50 μl solidi-
fied matrigel (BD Biosciences) in MEBM basal medium
without phenol red (Lonza CC-3153, Walkersville, MD,
USA) supplemented with bullet kit components except
for BPE (Lonza CC-4156), 10% charcoal FBS and 2%
matrigel, in the presence of 10 nM estrogen and in the
absence or presence of 2 μg/ml doxycycline. Medium
was changed every three days. Brightfield pictures show
mass structures that MCF-7 cells form in matrigel after
three weeks. MCF-7 cells were also fixed directly in cul-
ture with 4% Formaldehyde and stained with propidium
iodide. Confocal analysis was performed using Laser
scanning spectral confocal microscope TCS SP2. Large,
intermediate and small mass structures were counted
and presented as percent of the total population.
Results
Estrogen perturbs the p53-Mdm2 pathway in breast
cancer cells
Estrogen receptor a positive (ERa+) breast cancer cells
often have wild-type p53 and estrogen stimulates prolif-
eration of these cells [2]. Protein levels of p53 and its
negative regulator Mdm2 normally oscillate [36]. This
oscillation is perturbed in MCF-7 breast cancer cells
that carry the mdm2 SNP309 T to a G change (T®G)
but is not perturbed in the breast cancer cell line ZR75-
1 that does not have this change [15]. Moreover, a
major survival advantage is seen in MCF-7 cells treated
with estrogen for five days as compared to 24 hours
[11,37,38]. Therefore, we examined the effect of five
days of estrogen treatment on the p53-dependent signal
transduction in MCF-7 and ZR75-1 cells. In MCF-7
cells, Mdm2 protein increased after five days of estrogen
treatment while surprisingly, p53 protein was not
decreased and showed a slight increase (Figure 1a, lanes
1 and 2). However, estrogen decreased basal levels of
puma and p21 transcripts (Figure 1d). To determine if
estrogen influenced p53-dependent signal transduction
after DNA damage, we treated the cells with the che-
motherapeutic drug etoposide. DNA damage by etopo-
side increased the p53 protein level in the MCF-7 cells
while estrogen treatment caused no further increase
(Figure 1a, compare lanes 1 and 3 and lanes 3 and 4, for
p53). Etoposide treatment also increased the Mdm2
protein level in MCF-7 cells and estrogen treatment for
five days caused little further increase (Figure 1a, com-
pare lanes 1 and 3 and lanes 3 and 4, for Mdm2). When
we examined the p53 transcriptional activity after drug
treatment we saw a statistically significant reduction
in the etoposide-mediated activation of the puma
gene after estrogen treatment however transcription of
the target genes mdm2 and p21 was not changed
(Figure 1d).
We also examined the influence of estrogen on the
p53-dependent signal transduction in ZR75-1 cells that
have been shown to have intact oscillations for p53 and
Mdm2 [15]. The addition of estrogen did not influence
the Mdm2 or p53 levels in these cells (Figure 1b, lanes
1-4, p53 and Mdm2). We saw that p53 levels increased
following DNA damage by the drug etoposide in ZR75-
1 cells (Figure 1b, lanes 3 and 4) and that estrogen did
not influence the etoposide-mediated activation of p53
target genes (Figure 1e).
In order to study the influence of estrogen-mediated
outcomes driven through upregulation of Mdm2 we
focused our attention on the MCF-7 cell line. Since
estrogen decreased transcription of the p53 pathway tar-
get puma following chemotherapeutic treatment with
etoposide, we examined if PUMA protein levels were
also reduced. In direct correspondence to the transcrip-
tion data (Figure 1d) PUMA protein was reduced fol-
lowing estrogen treatment and this was also seen when
p53 was activated by etoposide treatment of MCF-7
cells (Figure 1c, compare lanes 1 and 2 and lanes 3 and
4, for PUMA). In addition, a coordinate increase in the
anti-apoptotic protein Bcl-2 was seen following estrogen
treatment (Figure 1c, compare lanes 1 and 2 and lane 3
and 4, for Bcl-2).
p53 and Mdm2 nuclear localization and chromatin
association are not influenced by estrogen treatment
Nuclear exclusion of p53 has been documented to occur
following estrogen treatment of breast cancer cells
[39,40]. We therefore evaluated if nuclear exclusion of
p53 could explain any of the estrogen-mediated changes
we saw in MCF-7 cells. We examined the effect of
estrogen treatment on the cellular localization of p53
and Mdm2 (Figure 2a). Localization of p53 was
unchanged by estrogen treatment of MCF-7 cells and
the Mdm2 in the same cells was predominantly
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nuclei shown). When the cells were treated with etopo-
side to damage the DNA and activate the p53 pathway
the p53 level increased in the nuclei and estrogen did
not block p53 protein localization (Figure 2a, ETOP
representative nuclei shown). Both Mdm2 and p53
were evident in punctate nuclear foci before and after
estrogen treatment.
To determine if estrogen decreased the ability of
nuclear p53 protein to interact with p53-responsive ele-
ments (p53-REs) of target genes we carried out quantita-
tive chromatin immunoprecipitation (ChIP) experiments
and examined p53 recruitment to the p53-REs of puma,
mdm2 and p21 genes in MCF-7 cells. Following etopo-
side treatment, p53 was recruited to the p53-REs of
puma, mdm2 and p21 genes (Figure 2b). Estrogen
Figure 1 Estrogen provokes increased Mdm2 and compromised transactivation of the p53 apoptotic target puma. MCF-7 and ZR75-1
cells were treated with 10 nM estrogen (E2) for five days and 50 μM etoposide (ETOP) for 48 hours. Western blot analysis of p53, Mdm2, and
Actin protein levels from whole cell lysates of MCF-7 (a) and ZR75-1 (b) cells respectively. (c) Protein levels of Puma, Bcl-2 and Actin from whole
cell lysates analyzed by Western blot. Quantitative real-time PCR (RT-PCR) was carried out for mRNA levels of puma, mdm2 and p21 genes in
MCF-7 (d) and ZR75-1 (e) cells respectively. Results were normalized to control samples and actin values. Graphs show means and standard
errors of two independent experiments. * P < 0.05 (Student t-test with * to indicate estrogen significantly influenced the transactivation of a p53
target gene).
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treated with 10 nM estrogen (E2) for five days and 50 μM etoposide (ETOP) for 48 hours. (a) Immunofluorescence was carried out for p53 and
Mdm2 proteins. Nuclear DNA was stained with DAPI. 400 μg of cross-linked and sonicated whole cell lysates were subjected to chromatin
immunoprecipitation (ChIP), using antibodies against p53 (b) or Mdm2 (c). ChIP with non-specific IgG was done to subtract the background.
Immunoprecipitated DNA was amplified by real-time quantitative PCR with primers and FAM-labeled probes for p53-REs in puma, mdm2 and p21
genes. Values were normalized to IgG and inputs, followed by normalization to the DSMO samples. Graphs show means and standard errors of
three independent experiments. The changes in relative binding of p53 and Mdm2 to the three different p53-REs were not significant (P > 0.05).
The P-values calculated by student T-test for the difference between with or without E2 were all between 0.1 and 0.25.
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chromatin interaction at any of the p53-REs. A trend
towards increased Mdm2 protein recruitment on the
chromatin was observed following etoposide plus estro-
gen treatment, however this change was not statistically
significant (Figure 2c).
Transactivation of p53 target genes following mdm2 gene
silencing
We predicted that the estrogen elicited growth promot-
ing effects resulted in part through the increase in Mdm2
and therefore reasoned that decreased mdm2 expression
would translate into reduced estrogen associated molecu-
lar changes in the cells. Because of the documented rela-
tionship between Mdm2 and p53 we continued to
examine this pathway. Mdm2 was knocked down by
siRNA to determine if any of the molecular outcomes
resulting from estrogen treatment required Mdm2. The
addition of siRNA to mdm2 was very effective at redu-
cing Mdm2 protein levels in estrogen and etoposide trea-
ted cells (Figure 3a, compare lanes 1-4 to lanes 5-8, for
Mdm2). Knockdown of mdm2 by siRNA did not increase
the p53 protein level in the absence or presence of etopo-
side (Figure 3a, compare lanes 1-4 to lanes 5-8, for p53).
However, knockdown of mdm2 by siRNA caused a dra-
matic increase in the level of p21 protein in the presence
or absence of estrogen (Figure 3a, compare lanes 1-4 to
lanes 5-8, for p21). Knockdown of mdm2 also resulted in
increased expression of p21 and puma mRNA as deter-
mined by quantitative RT-PCR (Figure 3b). This suggests
that while p53 protein did not increase following Mdm2
knockdown, the p53-dependent signal transduction path-
way was activated. The increased p21 protein observed
could therefore result from both p53-dependent regula-
tion of transcription and p53-independent regulation by
loss of Mdm2-mediated p21 degradation.
Inducible Mdm2 knockdown inhibits estrogen-mediated
MCF-7 and T-47D cell proliferation
To determine the contribution of Mdm2 or p53 to the
estrogen-induced cell proliferation, we generated induci-
ble short-hairpin RNA constructs (shRNAs) targeting
mdm2 or p53 using the mir-30 design (a generous gift
from Agustin Chicas and Scott Lowe). These shRNA
constructs and control constructs were transduced into
the MCF-7 cells and stable clones were selected. As
s h o w ni nF i g u r e4 ai n d u c t i o no fmdm2 shRNA reduced
Mdm2 protein while similar induction of the control
vector construct did not (Figure 4a, compare lanes 2
and 4 to lanes 6 and 8, for Mdm2). The induction of
mdm2 shRNA also resulted in a dramatic increase in
p21 protein (Figure 4a, compare lanes 2 and 4 to lanes
6 and 8, for p21). This was observed for multiple clones
as well as a selected pool (data not shown).
Induced knockdown of mdm2 repressed estrogen-
mediated cell proliferation, while the control vector
Figure 3 Gene silencing of MDM2 by siRNA potentiates p53 transactivation in the presence of estrogen. MCF-7 cells were transfected
with 100 nM non-specific or mdm2 siRNA. 24 hours following transfection, cells were treated with 10 nM estrogen (E2) for 24 hours and 50 μM
etoposide (ETOP) for 3 hours. (a) Western blot analysis of Mdm2, p53, p21 and Actin protein levels from whole cell lysates. (b) Quantitative real-
time RT-PCR for mRNA levels of puma, p21 and mdm2 genes in MCF-7 cells. Results were normalized to control samples and actin values.
Graphs show means and standard errors of two independent experiments.
Brekman et al. Breast Cancer Research 2011, 13:R3
http://breast-cancer-research.com/content/13/1/R3
Page 7 of 14Figure 4 Mdm2 knockdown in estrogen-treated MCF-7 cells inhibits cell proliferation. Clonal MCF-7 cell lines with mdm2 shRNA or control
vector were treated with 2 μg/ml doxycycline (DOX) for three days to induce shRNA expression, followed by 10 nM estrogen (E2) for five days in
the presence of DOX. (a) Western blot analysis of Mdm2, p53, p21 and Actin protein levels from whole cell lysates. (b) Number of cells was
determined by Guava Viacount assay. 10,000 cells were seeded at beginning of treatments. (c) Fluorescence activated cell sorting (FACS). Cells
were harvested, fixed in 30% ethanol, and cellular DNA was stained with propidium iodide. (d) Western blot analysis of Bcl-2 and Actin protein
levels from whole cell lysates. (e) MCF-7 cells, grown in matrigel for three weeks, formed mass structures of three sizes: large, intermediate and
small. (f) MCF-7 cells, grown in matrigel for three weeks in the presence of 10 nM estrogen and in the absence or presence of 2 μg/ml
doxycycline, were fixed and stained with propidium iodide. Masses of different sizes (large, intermediate and small) were counted and presented
as percent of the total population. On average, a total of 300 masses were counted. Averages of three independent experiments are shown. The
significance in the percent change of large and small masses was determined by the Student t-test (P < 0.05).
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file was examined we saw a reduction in S phase cells
a n da ni n c r e a s ei nG 1p h a s ep o p u l a t i o n sf o l l o w i n g
Mdm2 knockdown (Figure 4c). No increase in cell death
was detected following Mdm2 knockdown (data not
shown), but we did see a decrease in the estrogen-
induced anti-apoptotic protein Bcl-2 (Figure 4d, com-
pare lanes 4 and 8).
In addition to examining the role of Mdm2 in cell
proliferation in 2D culture, we also examined the effect
of Mdm2 knockdown on estrogen treated MCF-7 cell
proliferation in matrigel (3D culture). Normal mammary
epithelial cells cultured in matrigel organize into polar,
acini-like structures, while mammary tumor cells con-
tinue to proliferate into disorganized masses [41] that
correlate with their gene expression profiles [42]. We
observed that MCF-7 cells grown in matrigel for three
weeks in the presence of estrogen formed masses of
three different sizes: large, intermediate and small
(Figure 4e). The intermediate mass structure resembled
the acinus in shape and size, but had a filled lumen, as
reported by Bissell laboratory [42] and data not shown.
Only a small percent of the structures (about 13%) had
an intermediate mass size, while about 42-45% of the
structures were either large or small (Figure 4f). Inter-
estingly, Mdm2 knockdown led to a substantial decrease
in the number of large structures and an increased
number of small structures (Figure 4f).
To determine if the ability of estrogen to activate cell
proliferation occurred strictly through inhibition of
wild-type p53 we generated, and examined, MCF-7 cells
with inducible shRNA to p53. Reduction of both p53
and p21 protein levels were seen following induction of
the p53 shRNA (Figure 5a). The addition of estrogen
robustly promoted MCF-7 cell proliferation while the
knockdown of p53 in the absence of estrogen gave
barely any proliferative increase (Figure 5b). Moreover,
no further increase of the estrogen-mediated prolifera-
tion was achieved by knockdown of p53 (Figure 5b).
This suggests that estrogen signaling promotes growth
through more pathways than simply blocking p53.
Importantly, estrogen’s impact strongly depended on
Mdm2, suggesting that the Mdm2 influence could also
have a p53-independent role.
To further test the p53-independent role of Mdm2 on
estrogen signaling we generated inducible shRNA clones
from the cell line T-47D that has mutant p53, a G/G
SNP309 genotype and is estrogen receptor positive.
Induction of shRNA to mdm2, but not the vector con-
trol, resulted in a decrease in Mdm2 protein without an
increase in p21 (Figure 5c, compare lanes 1-2 and 5-6).
The addition of estrogen caused a robust increase of
Mdm2 that was partially decreased by shRNA induction
(Figure 5c, compare lane 3 to lane 4). The addition of
estrogen reduced the p21 protein levels (Figure 5c, lanes
3-4 and 7-8) and mdm2 shRNA induction did not res-
cue this reduction (Figure 5c, lane 4). Moreover, the
addition of estrogen did not decrease oncogenic mutant
p53 (in fact a slight increase was observed). Due to the
decreased p21 following estrogen treatment, but the lack
of increased p21 following mdm2 shRNA induction, it is
unclear if Mdm2 is directly degrading p21 in T-47D
cells. Importantly, estrogen promoted T-47D cell growth
and the depletion of Mdm2 decreased this growth pro-
moting effect (Figure 5d). Estrogen induced growth was
not reduced by induction of the vector control. There-
fore a p53-independent role of Mdm2 for activation of
T-47D cell proliferation was demonstrated.
Combination of Mdm2 knockdown and etoposide
treatment improves growth inhibition of breast cancer
cells
Because Mdm2 knockdown decreased estrogen-mediated
cell proliferation we reasoned that depletion of Mdm2 in
MCF-7 cells, in combination with the chemotherapeutic
drug etoposide would demonstrate a more robust cell
cycle checkpoint response than etoposide alone. We
examined the cell proliferation of MCF-7 cells with induci-
ble shRNA to mdm2. Estrogen activated proliferation was
inhibited to the same extent by either etoposide or
induced shRNA to mdm2 (Figure 6a). The combination of
estrogen and induced shRNA improved the growth inhibi-
tion of the estrogen treated cells (Figure 6a). Proliferation
without estrogen addition was very low. We examined the
n u m b e ro fc e l l si na ne s t r o g e np r o m o t e dg r o w t hp h a s e
following treatment with etoposide or with etoposide and
knockdown of Mdm2. When Mdm2 was present etopo-
side treatment caused the cells to pile up in the G2/M cell
cycle stage but when shRNA was induced to knockdown
Mdm2 the G2 population was reduced and the cells
shifted to a more G1 arrest like state (Figure 6b). This G1
checkpoint observed in the mdm2 shRNA MCF-7 cells
with etoposide and Mdm2 knockdown correlated with
increased expression of p21 (Figure 4a).
Discussion
Estrogen receptor a (ERa) positively regulates growth
and development of various tissues, and promotes
increased proliferation of breast cancer cells [10]. Based
on emerging data, the delicate balance between the
opposing functions of p53 and ERa appears to be dis-
rupted in breast cancer cells that over-express the
Mdm2 oncogene. Soon after Mdm2 was discovered,
ERa was shown to associate with high levels of Mdm2
in breast tumors [7,43,44]. In addition, the estrogen-
dependent increase in Mdm2 has been associated with
p53 and ERa recruitment to the mdm2 gene promoter
[8,18]. Our current work has addressed the central
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by estrogen and its direct influence on wild-type p53
protein function and breast cancer cell proliferation.
We studied the mechanism by which estrogen might
influence the p53 pathway in breast cancer cells with
wild-type p53 by determining p53 and Mdm2 protein
levels and the trans-activation properties of p53 in the
MCF-7 (mdm2 T/G SNP309) breast cancer cell line. We
also examined the influence of estrogen on isogenic
MCF-7 cell lines with inducible ("tet-on”)s h o r t - h a i r p i n
RNA to knockdown p53 or mdm2. We observed that
when MCF-7 cells were treated with estrogen, the Mdm2
protein level increased; however unlike in the central
p53-Mdm2 dogma, the p53 protein level did not decrease
(but slightly increased). Interestingly the ability of p53 to
activate transcription was decreased by estrogen and this
was relieved by knockdown of Mdm2. The increase in
Mdm2 protein in the presence of estrogen was in agree-
ment with previously published data, however, the sus-
tained p53 protein stability with increased Mdm2 has not
been previously reported and suggests a higher level of
complexity for the Mdm2 oncogenic targets. The nega-
tive auto-regulatory feedback loop that exists between
p53 and Mdm2 has been shown to be disrupted in cells
that carry the G allele in the mdm2 gene promoter
(SNP309) [15]. The trans-activation ability of p53 varies
with the nature of p53-activating stimuli, the cell type
and the duration of the activation signal [45,46]. Our
data implicates estrogen and ERa as variables that can
decrease the trans-activation ability of p53.
In a recent study of gene expression profiles that co-
cluster with ERa in breast tumors, it was shown that
puma is among the genes that are down-regulated after
estrogen treatment [47]. Estrogen has been shown to
inhibit apoptosis in MCF-7 cells by inducing bcl-2 [12].
We observed that estrogen increased proliferation
potentially by blocking cell cycle checkpoints. It was
interesting that we saw a coordinated up-regulation of
Bcl-2 and down-regulation of PUMA protein levels
in MCF-7 cells suggesting a need to signal for the
Figure 5 p53 knockdown in estrogen-treated MCF-7 cells does not promote cell proliferation and Mdm2 knockdown in estrogen-
treated T-47D cells decreases cell proliferation. Clonal MCF-7 cell lines with p53 shRNA or control vector were treated with 2 μg/ml
doxycycline (DOX) for three days to induce shRNA expression, followed by 10 nM estrogen (E2) for five days in the presence of DOX. (a)
Western blot analysis of p53, p21 and Actin protein levels from whole cell lysates. (b) Number of cells was determined by Guava Viacount assay.
10,000 cells were seeded at beginning of treatments. (c and d) Clonal T-47D cell lines with mdm2 shRNA or control vector were treated with 2
μg/ml doxycycline (DOX) for three days to induce shRNA expression, followed by 10 nM estrogen (E2) for five days in the presence of DOX. (c)
Western blot analysis of Mdm2, p53, p21 and Actin protein levels from whole cell lysates. (d) Number of cells was determined by Guava
Viacount assay. A total of 10,000 cells were seeded at beginning of treatments.
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tion. Estrogen-derived oxidants cause DNA damage by
oxidative stress and DNA adduct formation [48-50] that
could signal for apoptosis. It is possible that the DNA-
damaging effects of estrogen in combination with sup-
pression of multiple cell cycle checkpoints set the stage
for cancer cells to emerge from cell populations sustain-
ing DNA damage. It is highly likely that estrogen acts in
a number of coordinated ways to block cell cycle check-
points through the p53 and Rb/E2F pathways. Estrogen
induces transient cyclical DNA methylation of active
promoters that leads to transcription inhibition by chan-
ging the histone code [51,52]. Estrogen inhibits resvera-
trol-activated p53 in MCF-7 cells in part by interfering
with post-translational modifications of p53 which are
essential for p53-dependent DNA binding and conse-
quent stimulation of downstream pathways [53]. Addi-
tionally, the estrogen-mediated increase in Mdm2
protein might lead to p300/CREB transcription co-acti-
vators ubiquitination and degradation that would result
in reduced acetylation of p53 [54,55]. The puma gene is
regulated by p300 [56]. Importantly, ERa can bind to
p53 directly and repress p53 transcription activation
[13,14]. In addition to p53, p73 has been shown to acti-
vate puma expression [57], therefore it is possible that
ERa and Mdm2 inhibit p73 transactivation. Estrogen
has been shown to up-regulate Myc [37] and the puma
gene contains E boxes for Myc binding adjacent to the
location of the p53 binding site [58]. This coordinated
binding of Myc and p53 or its family members could
have implications for the inhibition of puma transcrip-
tion. However, the cooperation of Myc with Mdm2 may
have even greater implications for tumor promotion
through cross-talk with the RB/E2F pathway as well as
the p53 pathway.
We have addressed the impact of estrogen on Mdm2
signal transduction that is both p53-dependent and p53-
independent. When either siRNA or shRNA was used to
knockdown Mdm2 in MCF-7 cells, the p53 protein level
did not increase, but the p53 target gene p21 was up-
regulated, suggesting activation of p53 transcriptional
activity. We demonstrated that knockdown of Mdm2
inhibited estrogen-induced proliferation of the MCF-7
cell line. While estrogen promoted MCF-7 cell prolifera-
tion, knockdown of wild-type p53 in MCF-7 cells did
not. Moreover, knockdown of Mdm2 in MCF-7 cells
inhibited cell proliferation to the same extent as the
DNA damaging agent etoposide and in combination
with etoposide it provoked a robust G1 arrest. Taken
together these data suggest that estrogen provokes both
a p53-independent and a p53-dependent role for Mdm2
activating the growth of MCF-7 cells. As further evi-
dence for the p53-independent role of Mdm2 in estro-
gen mediated proliferation, we demonstrated that
knockdown of Mdm2 inhibited estrogen-induced prolif-
eration of the mutant p53 containing cell line T-47D.
Figure 6 Combination knockdown of Mdm2 with etoposide treatment improves growth inhibition of breast cancer cells. Clonal MCF-7
cell line with mdm2 shRNA was treated with 2 μg/ml doxycycline (DOX) for three days to induce shRNA expression, followed by 10 nM
estrogen (E2) for five days and 50 μM etoposide (ETOP) in the presence of DOX. (a) Number of cells was determined by Guava Viacount assay.
10,000 cells were seeded at beginning of treatments. (b) Fluorescence activated cell sorting (FACS). Cells were harvested, fixed in 30% ethanol,
and cellular DNA was stained with propidium iodide. (c) A model illustrating that Mdm2 plays a central role in estrogen-mediated breast cancer
cell proliferation.
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reduced p21 protein the knockdown of Mdm2 in T-47D
cells did not increase p21 protein as it did in MCF-7
cells. Recently many breast cancer cell lines were classi-
fied as a subtype called senescent cell progenitors
(SCPs), which associates with cellular senescence follow-
ing loss of ERa expression and increased expression of
p21 [59]. MCF-7 and T-47D cells fall into the SCP sub-
type. For the SCP subtype activation of ERa by estrogen
protects the cells from senescence. It would be interest-
ing to determine if knockdown of Mdm2 would induce
senescence of SCP subtype breast cancers. Combination
therapies involving re-activation of checkpoint pathways
blocked by Mdm2 (by decreasing Mdm2 protein) may
increase the efficacy of killing ERa+ breast cancers.
A p53-independent role of Mdm2 has been documented
to confer TGFb resistance in human mammary epithe-
lial cells [60].
The proliferative advantage conferred by estrogen was
observed for both the MCF-7 breast cancer cells and the
T-47D breast cancer cells. Moreover, we reproducibly
observed a more robust influence of estrogen on MCF-7
cells than on T-47D cells. It is possible that this is due to
the fact that T-47D cells have mutant p53 and therefore
estrogen would only influence p53-independent signal
transduction. In MCF-7 cells, with wild-type p53, estrogen
can impact both p53-dependent as well as p53-indepen-
dent pathways. The estrogen proliferative advantage con-
ferred to MCF-7 cells was visible in 3D culture as well as
in 2D culture. MCF-7 cells have a mass-like morphology
in matrigel, that is similar in size to the acinus, but has a
filled lumen indicative of an intermediate aggressive breast
cancer cell morphology [42]. We observed that MCF-7
cells formed large mass-like structures in 3D and that
these structures were replaced with small structures when
Mdm2 was knocked down, suggesting that Mdm2 may be
important for invasive behavior of breast cancer cells.
Further studies on the role of Mdm2 in aggressive meta-
static cells need to be conducted.
Conclusions
Herein we demonstrated that estrogen modestly inhibits
p53 transactivation of target genes in ERa+ breast can-
cer cells but robustly blocks a proliferative checkpoint
pathway through the upregulation of Mdm2. We have
demonstrated that estrogen uses an Mdm2-mediated
pathway to provoke cell proliferation and that this path-
way facilitates p53-independent signal transduction in
addition to the capacity to inhibit wild-type p53 func-
tion. Therefore, in ERa+ breast cancer Mdm2 may
antagonize multiple proliferative checkpoints in a way
reminiscent of viral oncogenes.
Abbreviations
AP1: activator protein 1; Bcl-2: B-cell lymphoma 2; cDNA: complimentary
DNA; ChIP: chromatin immunoprecipitation; DAPI: 4’,6-diamidino-2-
phenylindole; DMSO: Dimethyl sulfoxide; DOX: doxycycline; E2: estrogen;
ERα: estrogen receptor alpha; ERα+: estrogen receptor alpha positive;
ETOP: etoposide; FACS: fluorescence-activate cell sorter; FBS: fetal bovine
serum; FITC: Fluorescein isothiocyanate; Mdm2: mouse double minute 2;
p53-RE: p53 response element; PBS: phosphate-buffered saline; PUMA:
p53-upregulated mediator of apoptosis; qRT-PCR: quantitative reverse
transcriptase polymerase chain reaction; RIPA: radio immunoprecipitation
buffer; rtTA: reverse tetracyline-dependent transactivator; shRNA: short
hairpin RNA; siRNA: small interfering RNA; SNP309: single nucleotide
polymorphism at position 309; SP1: specificity protein 1; SCP: senescent cell
progenitors.
Acknowledgements
The Breast Cancer Research Foundation supported this project and
infrastructure support was provided from the National Institutions of Health
Grant Number RR03037 from the National Center for Research Resources. An
NSF grant to J.B., MCB-0744316, partially supported A.B.. We thank Agustin
Chicas and Scott Lowe for assistance with construction of the inducible
shRNA plasmid constructs. Summer undergraduate students Danielle Pasquel
and Patricia Garcia are thanked for help with plasmid construction. David
Foster, Inga Reynisdóttir and Gu Xiao are thanked for comments on the
manuscript and members of the Bargonetti lab are acknowledged for
helpful discussion.
Authors’ contributions
JB and AB wrote the manuscript. JB conceptualized and designed the study.
AB designed and carried-out the experiments. JB, AB, AP and NK worked on
vector-shRNA cloning and generation of clonal MCF-7 and T-47D cell lines
with inducible mdm2 and p53 shRNA constructs. KES contributed to study
conception and design, and set-up of estrogen treatment conditions. All
authors read, critiqued and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 8 July 2010 Revised: 17 November 2010
Accepted: 11 January 2011 Published: 11 January 2011
References
1. Vogelstein B, Lane D, Levine AJ: Surfing the p53 network. Nature 2000,
408:307-310.
2. Lacroix M, Toillon RA, Leclercq G: p53 and breast cancer, an update.
Endocr Relat Cancer 2006, 13:293-325.
3. Pharoah PD, Day NE, Caldas C: Somatic mutations in the p53 gene and
prognosis in breast cancer: a meta-analysis. Br J Cancer 1999,
80:1968-1973.
4. Hartmann A, Blaszyk H, Kovach JS, Sommer SS: The molecular
epidemiology of p53 gene mutations in human breast cancer. Trends
Genet 1997, 13:27-33.
5. Momand J, Jung D, Wilczynski S, Niland J: The MDM2 gene amplification
database. Nucleic Acids Res 1998, 26:3453-3459.
6. Bond GL, Hirshfield KM, Kirchhoff T, Alexe G, Bond EE, Robins H, Bartel F,
Taubert H, Wuerl P, Hait W, Toppmeyer D, Offit K, Levine AJ: MDM2
SNP309 Accelerates Tumor Formation in a Gender-Specific and
Hormone-Dependent Manner. Cancer Res 2006, 66:5104-5110.
7. Sheikh MS, Shao Z, Hussain A, Fontana JA: The p53-binding protein
MDM2 gene is differentially expressed in human breast carcinoma.
Cancer Res 1993, 53:3226-3228.
8. Phelps M, Darley M, Primrose JN, Blaydes JP: p53-independent activation
of the hdm2-P2 promoter through multiple transcription factor response
elements results in elevated hdm2 expression in estrogen receptor
alpha-positive breast cancer cells. Cancer Res 2003, 63:2616-2623.
9. Martin M: Molecular biology of breast cancer. Clin Transl Oncol 2006,
8:7-14.
10. Pearce ST, Jordan VC: The biological role of estrogen receptors alpha and
beta in cancer. Crit Rev Oncol Hematol 2004, 50:3-22.
Brekman et al. Breast Cancer Research 2011, 13:R3
http://breast-cancer-research.com/content/13/1/R3
Page 12 of 1411. Rodrik V, Zheng Y, Harrow F, Chen Y, Foster DA: Survival signals generated
by estrogen and phospholipase D in MCF-7 breast cancer cells are
dependent on Myc. Mol Cell Biol 2005, 25:7917-7925.
12. Perillo B, Sasso A, Abbondanza C, Palumbo G: 17beta-estradiol inhibits
apoptosis in MCF-7 cells, inducing bcl-2 expression via two estrogen-
responsive elements present in the coding sequence. Mol Cell Biol 2000,
20:2890-2901.
13. Liu W, Konduri SD, Bansal S, Nayak BK, Rajasekaran SA, Karuppayil SM,
Rajasekaran AK, Das GM: Estrogen receptor-alpha binds p53 tumor
suppressor protein directly and represses its function. J Biol Chem 2006,
281:9837-9840.
14. Sayeed A, Konduri SD, Liu W, Bansal S, Li F, Das GM: Estrogen receptor
alpha inhibits p53-mediated transcriptional repression: implications for
the regulation of apoptosis. Cancer Res 2007, 67:7746-7755.
15. Hu W, Feng Z, Ma L, Wagner J, Rice JJ, Stolovitzky G, Levine AJ: A single
nucleotide polymorphism in the MDM2 gene disrupts the oscillation of
p53 and MDM2 levels in cells. Cancer Res 2007, 67:2757-2765.
16. Lukas J, Gao DQ, Keshmeshian M, Wen WH, Tsao-Wei D, Rosenberg S,
Press MF: Alternative and aberrant messenger RNA splicing of the mdm2
oncogene in invasive breast cancer. Cancer Res 2001, 61:3212-3219.
17. Turbin DA, Cheang MC, Bajdik CD, Gelmon KA, Yorida E, De Luca A,
Nielsen TO, Huntsman DG, Gilks CB: MDM2 protein expression is a
negative prognostic marker in breast carcinoma. Mod Pathol 2006,
19:69-74.
18. Kinyamu HK, Archer TK: Estrogen receptor-dependent proteasomal
degradation of the glucocorticoid receptor is coupled to an increase in
mdm2 protein expression. Mol Cell Biol 2003, 23:5867-5881.
19. Saji S, Okumura N, Eguchi H, Nakashima S, Suzuki A, Toi M, Nozawa Y,
Hayashi S: MDM2 enhances the function of estrogen receptor alpha in
human breast cancer cells. Biochem Biophys Res Commun 2001,
281:259-265.
20. Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, Arva NC, Bargonetti J,
Bartel F, Taubert H, Wuerl P, Onel K, Yip L, Hwang SJ, Strong LC, Lozano G,
Levine AJ: A single nucleotide polymorphism in the MDM2 promoter
attenuates the p53 tumor suppressor pathway and accelerates tumor
formation in humans. Cell 2004, 119:591-602.
21. Arva NC, Gopen TR, Talbott KE, Campbell LE, Chicas A, White DE, Bond GL,
Levine AJ, Bargonetti J: A chromatin associated and transcriptionally
inactive p53-MDM2 complex occurs in MDM2 SNP 309 homozygous
cells. J Biol Chem 2005, 280:26776-26787.
22. Juven T, Barak Y, Zauberman A, George DL, Oren M: Wild type p53 can
mediate sequence-specific transactivation of an internal promoter
within the mdm2 gene. Oncogene 1993, 8:3411-3416.
23. Oren M, Damalas A, Gottlieb T, Michael D, Taplick J, Leal JF, Maya R,
Moas M, Seger R, Taya Y, Ben-Ze’ev A: Regulation of p53: intricate loops
and delicate balances. Biochem Pharmacol 2002, 64:865-871.
24. Moll UM, Petrenko O: The MDM2-p53 interaction. Mol Cancer Res 2003,
1:1001-1008.
25. Momand J, Zambetti GP, Olson DC, George D, Levine AJ: The mdm-2
oncogene product forms a complex with the p53 protein and inhibits
p53 mediated transactivation. Cell 1992, 69:1237-1245.
26. Oliner JD, Pietenpol JA, Thiagalingam S, Gyuris J, Kinzler KW, Vogelstein B:
Oncoprotein MDM2 conceals the activation domain of tumour
suppressor p53. Nature 1993, 362:857-860.
27. Wu X, Bayle JH, Olson D, Levine AJ: The p53-mdm-2 autoregulatory
feedback loop. Genes Dev 1993, 7:1126-1132.
28. Thut CJ, Goodrich JA, Tjian R: Repression of p53-mediated transcription
by MDM2: a dual mechanism. Genes Dev 1997, 11:1974-1986.
29. Minsky N, Oren M: The RING domain of Mdm2 mediates histone
ubiquitylation and transcriptional repression. Mol Cell 2004, 16:631-639.
30. Jin Y, Lee H, Zeng SX, Dai MS, Lu H: MDM2 promotes p21waf1/cip1
proteasomal turnover independently of ubiquitylation. Embo J 2003,
22:6365-6377.
31. Vazquez A, Bond EE, Levine AJ, Bond GL: The genetics of the p53 pathway,
apoptosis and cancer therapy. Nat Rev Drug Discov 2008, 7:979-987.
32. Vousden KH, Lane DP: p53 in health and disease. Nat Rev Mol Cell Biol
2007, 8:275-283.
33. Chipuk JE, Bouchier-Hayes L, Kuwana T, Newmeyer DD, Green DR: PUMA
couples the nuclear and cytoplasmic proapoptotic function of p53.
Science 2005, 309:1732-1735.
34. Jordan VC, O’Malley BW: Selective estrogen-receptor modulators and
antihormonal resistance in breast cancer. JC l i nO n c o l2007,
25:5815-5824.
35. Kaeser MD, Iggo RD: Chromatin immunoprecipitation analysis fails to
support the latency model for regulation of p53 DNA binding activity in
vivo. Proc Natl Acad Sci USA 2002, 99:95-100.
36. Lev Bar-Or R, Maya R, Segel LA, Alon U, Levine AJ, Oren M: Generation of
oscillations by the p53-Mdm2 feedback loop: a theoretical and
experimental study. Proc Natl Acad Sci USA 2000, 97:11250-11255.
37. Rodrik V, Gomes E, Hui L, Rockwell P, Foster DA: Myc stabilization in
response to estrogen and phospholipase D in MCF-7 breast cancer cells.
FEBS Lett 2006, 580:5647-5652.
38. Shanmugam M, Krett NL, Maizels ET, Cutler RE Jr, Peters CA, Smith LM,
O’Brien ML, Park-Sarge OK, Rosen ST, Hunzicker-Dunn M: Regulation of
protein kinase C delta by estrogen in the MCF-7 human breast cancer
cell line. Mol Cell Endocrinol 1999, 148:109-118.
39. Moll UM, Riou G, Levine AJ: Two distinct mechanisms alter p53 in breast
cancer: mutation and nuclear exclusion. Proc Natl Acad Sci USA 1992,
89:7262-7266.
40. Molinari AM, Bontempo P, Schiavone EM, Tortora V, Verdicchio MA,
Napolitano M, Nola E, Moncharmont B, Medici N, Nigro V, Armetta I,
Abbondanza C, Puca GA: Estradiol induces functional inactivation of p53
by intracellular redistribution. Cancer Res 2000, 60:2594-2597.
41. Bissell MJ, Radisky DC, Rizki A, Weaver VM, Petersen OW: The organizing
principle: microenvironmental influences in the normal and malignant
breast. Differentiation 2002, 70:537-546.
42. Kenny PA, Lee GY, Myers CA, Neve RM, Semeiks JR, Spellman PT, Lorenz K,
Lee EH, Barcellos-Hoff MH, Petersen OW, Gray JW, Bissell MJ: The
morphologies of breast cancer cell lines in three-dimensional assays
correlate with their profiles of gene expression. Mol Oncol 2007, 1:84-96.
43. Gudas JM, Oka M, Diella F, Trepel J, Cowan KH: Expression of wild-type
p53 during the cell cycle in normal human mammary epithelial cells.
Cell Growth Differ 1994, 5:295-304.
44. Hori M, Shimazaki J, Inagawa S, Itabashi M: Overexpression of MDM2
oncoprotein correlates with possession of estrogen receptor alpha and
lack of MDM2 mRNA splice variants in human breast cancer. Breast
Cancer Res Treat 2002, 71:77-83.
45. Paris R, Henry RE, Stephens SJ, McBryde M, Espinosa JM: Multiple p53-
independent gene silencing mechanisms define the cellular response to
p53 activation. Cell Cycle 2008, 7:2427-2433.
46. Espinosa JM: Mechanisms of regulatory diversity within the p53
transcriptional network. Oncogene 2008, 27:4013-4023.
47. Tozlu S, Girault I, Vacher S, Vendrell J, Andrieu C, Spyratos F, Cohen P,
Lidereau R, Bieche I: Identification of novel genes that co-cluster with
estrogen receptor alpha in breast tumor biopsy specimens, using a
large-scale real-time reverse transcription-PCR approach. Endocr Relat
Cancer 2006, 13:1109-1120.
48. Mobley JA, Brueggemeier RW: Estrogen receptor-mediated regulation of
oxidative stress and DNA damage in breast cancer. Carcinogenesis 2004,
25:3-9.
49. Chen Y, Liu X, Pisha E, Constantinou AI, Hua Y, Shen L, van Breemen RB,
Elguindi EC, Blond SY, Zhang F, Bolton JL: A metabolite of equine
estrogens, 4-hydroxyequilenin, induces DNA damage and apoptosis in
breast cancer cell lines. Chem Res Toxicol 2000, 13:342-350.
50. Yared E, McMillan TJ, Martin FL: Genotoxic effects of oestrogens in breast
cells detected by the micronucleus assay and the Comet assay.
Mutagenesis 2002, 17:345-352.
51. Metivier R, Gallais R, Tiffoche C, Le Peron C, Jurkowska RZ, Carmouche RP,
Ibberson D, Barath P, Demay F, Reid G, Benes V, Jeltsch A, Gannon F,
Salbert G: Cyclical DNA methylation of a transcriptionally active
promoter. Nature 2008, 452:45-50.
52. Kangaspeska S, Stride B, Metivier R, Polycarpou-Schwarz M, Ibberson D,
Carmouche RP, Benes V, Gannon F, Reid G: Transient cyclical methylation
of promoter DNA. Nature 2008, 452:112-115.
53. Zhang S, Cao HJ, Davis FB, Tang HY, Davis PJ, Lin HY: Oestrogen inhibits
resveratrol-induced post-translational modification of p53 and apoptosis
in breast cancer cells. Br J Cancer 2004, 91:178-185.
54. Jin Y, Zeng SX, Dai MS, Yang XJ, Lu H: MDM2 inhibits PCAF (p300/CREB-
binding protein-associated factor)-mediated p53 acetylation. J Biol Chem
2002, 277:30838-30843.
Brekman et al. Breast Cancer Research 2011, 13:R3
http://breast-cancer-research.com/content/13/1/R3
Page 13 of 1455. Jin Y, Zeng SX, Lee H, Lu H: MDM2 mediates p300/CREB-binding protein-
associated factor ubiquitination and degradation. J Biol Chem 2004,
279:20035-20043.
56. Iyer NG, Chin SF, Ozdag H, Daigo Y, Hu DE, Cariati M, Brindle K, Aparicio S,
Caldas C: p300 regulates p53-dependent apoptosis after DNA damage in
colorectal cancer cells by modulation of PUMA/p21 levels. Proc Natl Acad
Sci USA 2004, 101:7386-7391.
57. Sun SH, Zheng M, Ding K, Wang S, Sun Y: A small molecule that disrupts
Mdm2-p53 binding activates p53, induces apoptosis, and sensitizes lung
cancer cells to chemotherapy. Cancer Biol Ther 2008, 7.
58. Fernandez PC, Frank SR, Wang L, Schroeder M, Liu S, Greene J, Cocito A,
Amati B: Genomic targets of the human c-Myc protein. Genes Dev 2003,
17:1115-1129.
59. Mumcuoglu M, Bagislar S, Yuzugullu H, Alotaibi H, Senturk S, Telkoparan P,
Gur-Dedeoglu B, Cingoz B, Bozkurt B, Tazebay UH, Yulug IG, Akcali KC,
Ozturk M: The ability to generate senescent progeny as a mechanism
underlying breast cancer cell heterogeneity. PLoS One 2010, 5:e11288.
60. Sun P, Dong P, Dai K, Hannon GJ, Beach D: p53-independent role of
MDM2 in TGF-beta1 resistance. Science 1998, 282:2270-2272.
doi:10.1186/bcr2804
Cite this article as: Brekman et al.: A p53-independent role of Mdm2 in
estrogen-mediated activation of breast cancer cell proliferation. Breast
Cancer Research 2011 13:R3.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Brekman et al. Breast Cancer Research 2011, 13:R3
http://breast-cancer-research.com/content/13/1/R3
Page 14 of 14